Orthotopic patient-derived xenografts of paediatric solid tumours

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice

(2016) Elizabeth C. Townsend et al.   CANCER CELL

A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds

(2016) Alejandra Bruna et al.   CELL

Patient-derived xenografts for childhood solid tumors: a valuable tool to test new drugs and personalize treatments

(2016) P. Zarzosa et al.   Clinical & Translational Oncology

The Childhood Solid Tumor Network: A new resource for the developmental biology and oncology research communities

(2016) Elizabeth Stewart et al.   DEVELOPMENTAL BIOLOGY

Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs

(2016) Marc Hafner et al.   NATURE METHODS

Preclinical Models Provide Scientific Justification and Translational Relevance for Moving Novel Therapeutics into Clinical Trials for Pediatric Cancer

(2015) D. M. Langenau et al.   CANCER RESEARCH

Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients

(2015) Marc van de Wetering et al.   CELL

Organoid Models of Human and Mouse Ductal Pancreatic Cancer

(2015) Sylvia F. Boj et al.   CELL

Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors

(2015) Khanh Do et al.   JOURNAL OF CLINICAL ONCOLOGY

High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response

(2015) Hui Gao et al.   NATURE MEDICINE

Pediatric solid tumor genomics and developmental pliancy

(2015) X Chen et al.   ONCOGENE

Genomic landscape of paediatric adrenocortical tumours

(2015) Emilia M. Pinto et al.   Nature Communications

Declining childhood and adolescent cancer mortality

(2014) Malcolm A. Smith et al.   CANCER

Functional Heterogeneity of Genetically Defined Subclones in Acute Myeloid Leukemia

(2014) Jeffery M. Klco et al.   CANCER CELL

Organoid Cultures Derived from Patients with Advanced Prostate Cancer

(2014) Dong Gao et al.   CELL

Genomic Landscape of Ewing Sarcoma Defines an Aggressive Subtype with Co-Association of STAG2 and TP53 Mutations

(2014) F. Tirode et al.   Cancer Discovery

Targeting the DNA Repair Pathway in Ewing Sarcoma

(2014) Elizabeth Stewart et al.   Cell Reports

Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma

(2014) Xiang Chen et al.   Cell Reports

Targeting Oxidative Stress in Embryonal Rhabdomyosarcoma

(2013) Xiang Chen et al.   CANCER CELL

Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51

(2013) Chengzhi Xie et al.   PLoS One

ChromHMM: automating chromatin-state discovery and characterization

(2012) Jason Ernst et al.   NATURE METHODS

The analysis of 2 × 2 contingency tables-Yet again

(2011) John T. E. Richardson   STATISTICS IN MEDICINE

Evaluation of homogenization techniques for the preparation of mouse tissue samples to support drug discovery

(2011) Xiaorong Liang et al.   Bioanalysis

Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma

(2010) Donna E. Reece et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges

(2009) Peter Atadja   CANCER LETTERS

In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma

(2009) E. M. Ocio et al.   HAEMATOLOGICA